
Listing of Claims:

1. A crystalline Form **1** of a compound having the structural formula:



2. The crystalline Form **1** of Claim 1, wherein the crystalline form is characterized by at least three x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°.

3. The crystalline Form **1** of Claim 1 or 2, wherein the crystalline form is characterized by at least four x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°.

4. The crystalline Form **1** of any one of Claims 1 to 3, wherein the crystalline form is characterized by at least five x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°.

5. The crystalline Form **1** of any one of Claims 1 to 4, wherein the crystalline form is characterized by at least six x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°.

6. The crystalline Form **1** of any one of Claims 1 to 5, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 13.3°, 14.9°, 20.2°, 20.8°, 22.2°, and 22.5°.

7. The crystalline Form **1** of any one of Claims 1 to 6, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0°, 10.2°, 12.3°, 12.7°, 13.3°, 14.9°, 15.3°, 20.2°, 20.8°, 21.3°, 22.2°, 22.5°, and 23.8°.

8. The crystalline Form **1** of any one of Claims 1 to 7, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0º, 10.2º, 11.0º, 11.4º, 11.8º, 12.3º, 12.7º, 13.3º, 14.9º, 15.3º, 16.1º, 17.4º, 20.2º, 20.8º, 21.3º, 22.2º, 22.5º, and 23.8º.

9. The crystalline Form **1** of any one of Claims 1 to 8, wherein the crystalline form is characterized by an XRPD substantially similar to **FIG. 1**.

10. The crystalline Form **1** of Claim 1, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 14.9º, 20.2º, and 20.8º.

11. The crystalline Form **1** of Claims 1 or 10, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0º, 14.9º, 20.2º, and 20.8º.

12. The crystalline Form **1** of any one of Claims 1, 10 or 11, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0º, 14.9º, 20.2º, 20.8º, and 22.2º.

13. The crystalline Form **1** of any one of Claims 1, or 10 to 12, wherein the crystalline form is characterized by x-ray powder diffraction peaks at 2Θ angles selected from 10.0º, 13.3º, 14.9º, 20.2º, 20.8º, and 22.2º.

14. The crystalline Form **1** of any one of Claims 1 to 13, wherein the crystalline form is anhydrous.

15. The crystalline Form **1** of any one of Claims 1 to 14, wherein the crystalline Form **1** is at least 90% a single crystalline form by weight.


16. The crystalline Form **1** of any one of Claims 1 to 15, wherein the crystalline Form **1** is at least 95% a single crystalline form by weight.

17. The crystalline Form **1** of any one of Claims 1 to 16, wherein the compound has a chemical purity of at least 90% by weight.

18. The crystalline Form **1** of any one of Claims 1 to 17, wherein the compound has a chemical purity of at least 95% by weight.

19. The crystalline Form **1** of any one of Claims 1 to 18, wherein the compound has a chemical purity of at least 99% by weight.

20. The crystalline Form **1** of any one of Claims 1 to 19, wherein the compound has the structural formula:



.

21. A pharmaceutical composition comprising the crystalline form of any one of Claims 1 to 20, and a pharmaceutically acceptable carrier or diluent.

22. Use of the crystalline form of any one of Claims 1 to 20, or the composition of Claim 21 in the manufacture of a medicament for treating a disease or disorder associated with cellular proliferation in a patient in need thereof.

23. The crystalline form of any one of Claims 1 to 20, or the composition of claim 21 for use in treating a disease of disorder associated with cellular proliferation in a patient in need thereof.

24. The use of Claim 22, or the crystalline form or the composition of Claim 23, wherein the disease is cancer.

25. The use, crystalline form or composition of Claim 24, wherein the cancer is selected from breast cancer, prostate cancer, colon cancer, renal cell carcinoma, glioblastoma

multiforme cancer, bladder cancer, melanoma, bronchial cancer, lymphoma, liver cancer, multiple myeloma, lymphoma, ovarian cancer, NSCL, pancreatic cancers, malignant rhabdoid tumor, synovial sarcoma, glioma.